Drug intelligence / Profile preview

CBA-1

Development stage: Unknown
Lead developer: Cargill
Modality: Microbiome Therapeutics
Administration: Oral

Overview

CBA-1 is a novel dietary fiber developed by Cargill. It is currently undergoing clinical trials to assess its gastrointestinal tolerability in healthy men and women at various dose levels and eating occasions. The studies involve administering the fiber in beverage form and monitoring for gastrointestinal effects.

Beyond the preview

Go deeper on CBA-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBA-1.

Explore the full profile